Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company’s Proposed Merger with Standard BioTools
Additionally, Madryn announced it has filed a preliminary proxy statement with the Securities and Exchange Commission (“SEC”) in order to solicit proxies in opposition to the Merger.
- Additionally, Madryn announced it has filed a preliminary proxy statement with the Securities and Exchange Commission (“SEC”) in order to solicit proxies in opposition to the Merger.
- That is why we intend to vote AGAINST the Merger at the upcoming Special Meeting on January 4, 2024.
- Additionally, we have taken steps to soon be in a position to actively solicit your votes AGAINST the Merger.
- In the meantime, we urge you to reach out to SomaLogic to express your views on the Merger.